Table 1.
Aorta and Temporal Artery Biopsies. Diagnostic Subsets and Comorbidities
| Case number within subsets | Diagnosis | Age | Gender | Race | Comorbidities | Prednisone dose mg/d* |
|---|---|---|---|---|---|---|
| Inflammatory aortic disease | ||||||
| 1 | GCA | 76 | F | W | hypertension | 2 |
| 2 | GCA | 81 | F | W | Polymyalgia rheumatica, hypertension, hyperlipidemia A-fib | 5 |
| 3 | GCA | 66 | M | W | none | 35 |
| 4 | GCA | 67 | F | W | MV prolapse hypertension | 0 |
| 5 | GCA | 71 | F | W | Hypertension, CAD | 0 |
| 6 | GCA | 70 | F | W | CAD | 0 |
| 7 | GCA | 65 | F | W | hyperlipidemia | 0 |
| 8 | GCA | 63 | F | W | CAD hypertension | 0 |
| 1 | TAK | 30 | M | W | none | 20 |
| 2 | TAK | 39 | F | W | none | 30 |
| 1 | FIA | 67 | M | W | Hypertension hyperlipidemia | 0 |
| 2 | FIA | 70 | F | C | CAD, CHF, A-fib, hypertension | 0 |
| 3 | FIA | 53 | M | Asian | none | 0 |
| 4 | FIA | 62 | F | W | Bicuspid Aortic, Valve, CAD Hypertension Hyperlipidemia | 0 |
| 5 | FIA | 45 | F | W | Hyperlipidemia | 0 |
| 6 | FIA | 82 | F | AA | A-fib, hypertension, Type 2 diabetes | 0 |
| Aortic aneurysm non-inflammatory Controls | ||||||
| 1 | 75 | F | W | hypertension | 0 | |
| 2 | 57 | F | W | Bicuspid AV | 0 | |
| 3 | 66 | M | W | CAD, hypertension, hyperlipidemia | 0 | |
| 4 | 69 | F | W | none | 0 | |
| 5 | 76 | F | W | Hypertension, hyperlipidemia | 0 | |
| 6 | 57 | F | W | none | 0 | |
| 7 | 25 | M | W | Bicuspid AV | 0 | |
| 8 | 32 | M | W | Bicuspid AV | 0 | |
| 9 | 78 | M | W | none | ||
| 10 | 65 | F | W | Hypertension, hyperlipidemia, A-fib | 0 | |
| 11 | 51 | M | W | Bicuspid AV | 0 | |
| 12 | 55 | F | W | Hypertension, Type 2 DM, hyperlipidemia, CAD | 0 | |
| 13 | 50 | F | W | Bicuspid AV | 0 | |
| 14 | 68 | M | W | none | 0 | |
| 15 | 47 | F | W | Bicuspid AV | 0 |
| Temporal artery biopsy | Diagnosis | Age | Gender | Race | Comorbidities | Prednisone-Dose @ bx (mg/d)** |
|---|---|---|---|---|---|---|
| 1 | GCA | 70 | M | W | Past history of PMR, ascending aortic aneurysm, stroke, kidney stones, obstructive sleep apnea | 40 |
| 2 | GCA | 70 | M | W | CABG x2, osteogenesis imperfecta, fractures, hearing loss, acute VL both eyes | 1000 |
| 3 | GCA | 77 | F | W | Left eye vision loss since birth, GERD, hypertension, osteoarthritis | 30 |
| 4 | GCA | 70 | F | W | osteoarthritis, migraine, carpal tunnel, sarcoidosis (lymph node Bx +1977)—resolved, MGUS, peripheral neuropathy | 40 |
| 5 | GCA | 81 | F | W | Prior history of breast CA, colon cancer and TIA | 10 |
| 1 | Control | 51 | F | W | DVT, stroke, antiphospholipid antibody syndrome, migraine, depression, Hashimoto thyroiditis | 40 |
| 2 | Control | 76 | F | Patient declined to state race | Basal cell carcinoma, COPD, CHF, depression, hypothyroidism, chronic migraine, hypertension, stroke, seizures | 80 |
| 3 | Control | 59 | F | W | Migraine, sensori-neural hearing loss, hypothyroidism | 60 |
| 4 | Control | 63 | F | W | GERD, asthma, depression, morphea, spinal stenosis, osteoarthritis irritable bowel syndrome, peptic ulcer disease | 60 |
| 5 | Control | 87 | F | W | RA, A. fib, aortic stenosis, sensorineural hearing loss, osteoporosis, COPD hyperparathyroidism | 60 |
| 6 | Control | 83 | M | W | Diverticulitis, GERD, obstructive sleep apnea, AAA (3.7 cm) | 40 |
*
None of the control aorta patients were receiving corticosteroids or other immunosuppressive agents None of the aortitis patients were receiving corticosteroids plus another immunosuppressive agent.
**
None of the GCA or temporal artery control patients were receiving corticosteroids plus another immunosuppressive agent.